Pfizer's Diflucan for S Africa "within weeks"
Pfizer and the South African Department of Health have announced thatdistribution of Diflucan (fluconazole) free to South African HIV/AIDS patients will begin at government hospitals and clinics "within weeks."
On February 21, Diflucan was approved in the country for the treatment of the fungal infection esophageal candidiasis, which is estimated to affect up to 40% of HIV/AIDS sufferers. It is already approved in South Africa as a treatment for cryptococcal meningitis.
The statement said that patients will receive the drug for as long as they need it, and those in the program will continue to receive it free when the program ends in December 2002. The program is expected to cost the company more than 375 million rand ($48 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze